Vireo Growth Inc. (VREOF) company profile
Close on Oct 19, 2026Market cap $406.23MP/E –Yield –
About Vireo Growth
Pharmaceutical Preparations, SIC 2834
Vireo Growth Inc. is a vertically integrated cannabis company that cultivates, manufactures, wholesales, and retails cannabis products. Its operations span three primary divisions: cultivation, production, and retail dispensaries. The company produces and packages cannabis items across multiple formats, including inhalables such as flower, concentrates, and vaporizers; ingestibles such as edibles, tablets, and tinctures; and topicals. Vireo Growth serves medical patients and adult-use consumers through its retail stores, while also supplying third-party licensed dispensaries through wholesale channels.
The company operates in six American states: Maryland, Minnesota, Missouri, Nevada, New York, and Utah. Its footprint includes 36 retail dispensaries along with dedicated cultivation and manufacturing facilities. The business employs over six hundred workers. Vireo Growth maintains its corporate headquarters in Minneapolis, Minnesota, and a registered office in Vancouver, British Columbia.
Summary of the business section of Vireo Growth's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vireo Growth Inc.
- Founded
- 2014
- Headquarters
- Minneapolis, MN
- Address
- 207 South 9th Street 55402
- Phone
- (612) 999-1606
- Website
- vireogrowth.com
- Employees
- 612, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- DAVIDSON & COMPANY LLP, Vancouver, BC
Stock & identifiers
- Ticker
- VREOF
- Exchange
- OTC
- IPO date
- Mar 22, 2019
- Shares outstanding
- 48M, Aug 14, 2026
- Public float
- $345.97M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Jun 5, 2026
- SEC CIK
- 1771706
- CUSIP
- 38238W103
- ISIN
- CA38238W1032
- FIGI
- BBG00NPL59T9
- Share class FIGI
- BBG001SNXQB0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Mazarakis | Chief Executive Officer, Director | 9,833,737 |
| Kyle Eugene Kingsley | Co-Executive Chairman, Director | 14,206,363 |
| Joseph Duxbury | Chief Accounting Officer | 136,333 |
| Sean Michael Apfelbaum | GC and Corporate Secretary | 271,188 |
| Amber Holly Shimpa | President | 1,119,965 |
| Tyson Macdonald | Chief Financial Officer | 7,416,021 |
| Michael L. Steiner | Director | 1,675,903 |
| Christopher Hagedorn | Director | 0 |
| Judd Theodore Nordquist | Director | 118,912 |
| Victor E. Mancebo | Director | 118,912 |
| Ross Michael Hussey | Director | 33,170 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Total | vs. prior year |
|---|---|---|---|---|---|
| John Mazarakis Chief Executive Officer and Co-Executive Chairman | $1 | $2.30M | $17.73M | $20.03M | +2404% |
| Tyson Macdonald Chief Financial Officer | $500.00K | $1.15M | $8.62M | $10.27M | +1160% |
| Sean Apfelbaum General Counsel | $145.83K | $300.00K | $128.80K | $574.63K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 6, 2026 we had 612 employees, 520 of whom were full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?